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A B S T R A C T
Heterogeneity in disease mechanisms between genetically distinct patients contributes to high attrition rates in
late stage clinical drug development. New personalized medicine strategies aim to identify predictive biomarkers
which stratify patients most likely to respond to a particular therapy. However, for complex multifactorial
diseases not characterized by a single genetic driver, empirical approaches to identifying predictive biomarkers
and the most promising therapies for personalized medicine are required. In vitro pharmacogenomics seeks to
correlate in vitro drug sensitivity testing across panels of genetically distinct cell models with genomic, gene
expression or proteomic data to identify predictive biomarkers of drug response. However, the vast majority of in
vitro pharmacogenomic studies performed to date are limited to dose-response screening upon a single viability
assay endpoint. In this article we describe the application of multiparametric high content phenotypic screening
and the theta comparative cell scoring method to quantify and rank compound hits, screened at a single con-
centration, which induce a broad variety of divergent phenotypic responses between distinct breast cancer cell
lines. High content screening followed by transcriptomic pathway analysis identified serotonin receptor mod-
ulators which display selective activity upon breast cancer cell cycle and cytokine signaling pathways correlating
with inhibition of cell growth and survival. These methods describe a new evidence-led approach to rapidly
identify compounds which display distinct response between different cell types. The results presented also
warrant further investigation of the selective activity of serotonin receptor modulators upon breast cancer cell
growth and survival as a potential drug repurposing opportunity.
1. Introduction
For many complex diseases, heterogeneity in the molecular me-
chanisms of disease onset and progression between distinct patients
contributes to high attrition in clinical drug development. Advances in
next generation sequencing (NGS) and classification of patients into
molecularly defined subgroups support personalized medicine strate-
gies, which utilize predictive biomarkers to identify patient subgroups,
which are most likely to respond to a specific therapy.1,2 In cancer,
highly selective drugs targeted at genetically defined clinical subtypes
has demonstrated significant success where drug mechanism-of-action
(MOA) can be directly mapped to amplifications or mutations of spe-
cific therapeutic targets or to key vulnerabilities such as DNA repair
defects.3–6 However, for the majority of patients, the underlying mo-
lecular drivers of disease are either unknown or complicated by
multiple genetic aberrations and redundant pathways confounding the
identification of the most promising therapeutic targets, candidate
drugs and biomarker strategies.
Recent advances of in vitro cell based assay screening technologies
that enable rapid screening of large numbers of approved drugs, ex-
perimental drugs and diverse chemical libraries across panels of ge-
netically distinct cell lines combined with genetic and proteomic pro-
filing are well placed to support more unbiased evidence-led preclinical
approaches to personalized medicine discovery.7,8 Advances in new cell
based assay technologies including automated high content imaging
and molecular cell profiling technologies (e.g. NGS and miniaturized
array based transcriptomic and proteomics) present new opportunities
for incorporating more relevant and informative models into drug dis-
covery.9 For example, the adaptation of patient-derived primary cell
samples for high throughput screening have supported the application
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of drug sensitivity and resistance testing (DSRT) to provide a more
patient-centric approach to drug discovery and development.10 In a
typical DSRT assay, cancer cells taken directly from patients are pur-
ified and placed in multi-well plates for screening of several hundred
clinically approved or experimental cancer drugs at multiple con-
centrations and cell viability is measured after 72 h (for example re-
ferences10–13). In leukemia where the ex vivo material (for example,
liquid biopsy samples) are more readily available for drug testing than
in solid tumors, patient-derived samples have recently been utilized for
potential drug repositioning10,14 and combined with molecular pro-
filing to identify biomarkers for personalized acute myeloid leukemia
(AML) therapy.10
In vitro pharmacogenomics describes the application of compound
screening across genetically distinct cell types and correlation of drug
sensitivity with genomic and gene expression datasets to elucidate drug
mechanism of action and identify biomarkers of response.15,16 Multiple
articles have described the application of high throughput in vitro
pharmacogenomics across genetically distinct panels of cancer cell lines
and large databases linking gene expression data and drug sensitivity
have been developed.17,18 However, the majority of DSRT and in vitro
pharmacogenomic studies performed to date have used single cell
viability endpoints, which include application to complex models and/
or patient biopsies.19 However, such single viability endpoints preclude
more detailed phenotypic response analysis of complex and diverse co-
culture, 3D cell models or other phenotypic endpoints which may fur-
ther inform clinical applications (e.g. cell motility, autophagy, DNA
damage/repair defects and heterogeneity at single cell level).
The integration of automated high-throughput microscope plat-
forms with the latest advances in multiparametric image analysis,
multivariate statistics, machine learning and new computational
biology resources enable more sophisticated classification of cell phe-
notypes across cell based assay systems at scale. These advances sup-
port the new disciplines of high content analysis and phenotypic pro-
filing which compare similarities and dissimilarities between drug MOA
across cell based assays.20–24 It is anticipated that further development
of these methods will better inform target identification, hit identifi-
cation and hit-to-lead medicinal chemistry programs in relevant models
of disease. Further integration of high content phenotypic profiling data
across well characterized patient-derived cells, and established cell line
panels with genomics, proteomics and computational biology ap-
proaches are also well placed to further advance in vitro pharmacoge-
nomics and drug repurposing studies.
We recently described the application of a method, Theta
Comparative Cell Scoring (TCCS), which uses multiparametric high
content imaging data to quantify how similar or dissimilar a compound
induced phenotype is between genetically distinct cell types.25,26 We
proposed that the TCCS method will support the application of in vitro
pharmacogenomic and drug repurposing studies beyond simple uni-
variate assay endpoints towards more complex assays, phenotypic
endpoints and novel therapeutic classes. Here, we describe the appli-
cation of a high content Cell Painting assay and the TCCS method to a
1280 compound FDA-approved small molecule library screen across a
panel of 8 genetically distinct human breast cancer cell lines. We used
the TCCS method to rank compounds which display the most divergent
phenotypic response across the breast cancer cell panel. We identified a
series of 4 known serotonin receptor modulators (fluvoxamine, cisa-
pride, protriptyline and triflupromazine) which rank among the top 12
compounds promoting the most distinct phenotypic response between
breast cancer cell line pairs. Transcriptomic pathway analysis per-
formed on the most potent serotonin modulator (triflupromazine)
Fig. 1. Summary of phenotypic screen. (A) Schematic of screening strategy. (B) Principal component analysis (PCA) of phenotypic screen. Data points color coded:
drug treatment, positive control (300 nM staurosporine) or negative control (0.1% DMSO). (C) PCA analysis of phenotypic screen color coded by cell line.
Multivariate Z’-factor analysis between negative (0.1% DMSO) and positive (0.3 μM staurosporine) controls by cell line is indicated in brackets.
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demonstrates selective down regulation of multiple cell cycle pathways
and upregulation of tumor necrosis factor (TNF) signaling pathways in
the most sensitive breast cancer cell type. Thus, combined high content
phenotypic screening, and pathway network analysis identifies an ex-
isting serotonin receptor modulator with selective activity upon breast
cancer cell cycle and TNF signaling pathways representing a potential
drug repurposing opportunity for specific breast cancer types.
2. Results and discussion
The Prestwick Chemical Library of 1280 FDA-approved compounds
at a single concentration of 1 μM was profiled in a phenotypic high-
content image based assay across eight breast cancer cell-lines
(HCC1569; HCC1954; KPL4; MCF7; MDA-MB-157; MDA-MB-231;
SKBR3; T47D) which are classified into three clinical subtypes; estrogen
receptor (ER) positive, HER2 amplified or triple negative (TN) for ER,
progesterone receptor and HER2 (Fig. 1A).
We sought to identify compounds that induced distinct phenotypic
responses between cell lines using a Cell Painting assay as an unbiased
phenotypic profiling method.21 We quantified multiple morphological
features from the images using CellProfiler image analysis software27
and aggregated single cell data to an image median. Each cell line has
different genetic backgrounds28 and such changes can drive phenotypic
differences between each cell line, for example, loss of E-cadherin is a
hallmark of epithelial to mesenchymal transition as it is a critical
component of epithelial cell-cell junctions29 and is often differentially
expressed between cell lines resulting in significant morphological
differences. Therefore, to allow comparison of cellular phenotypes
across the panel of cell lines, compound treated cell feature data was
normalized and standardized to the plate negative control values and
visualized using principal component analysis to reveal a clear se-
paration between the positive (300 nM staurosporine) and negative
control (0.1% DMSO) treatments (Fig. 1B and C). This step effectively
removed the variation in the basal cell line morphologies
(Supplementary Fig. S1). This allowed us to compare the effect of
compound treatment on the phenotypic response across a morpholo-
gically distinct cell-line panel (Fig. 1A). Assay robustness was con-
firmed by using a multivariate Z’ factor analysis between negative and
positive controls30 giving a score of 0.6 for the pooled cell-lines, and
greater than 0.7 for individual cell-lines (Fig. 1A) demonstrating a ro-
bust screening assay. For each phenotypically active compound in the
Prestwick FDA-approved library (Table 1), the difference in response
between pairs of cell-lines was measured using the TCCS method,26 and
a rank product of the delta theta score was used to list compound-cell
line pairs in terms of the greatest differential effects; the 266 com-
pound-cell line pairs are shown in Supplementary Table S1. Compounds
that demonstrated distinct phenotypic responses between cell lines
were confirmed by replication studies and triaged by selecting those
with interesting MOAs, for example by removing known anti-cancer
cytotoxic compounds, including several microtubule disruptors: twelve
hits were selected for further study (Fig. 2 and Table 2).
Using GFP-NucLight expressing breast cancer cells, selected hits
were tested as an 8 point semi-log range of concentrations (0.3 nM to
1 µM) and cell proliferation was monitored over 72 h in the IncuCyte
ZOOM microscope. GFP cell-count normalized to the DMSO negative
control was used as a measure of cell proliferation over 72 h (Fig. 3) and
despite a selection criteria aiming to limit overtly cytotoxic compounds,
11 out of the 12 compounds demonstrated a reduction in cell-count in
at least one of the cell-lines at the higher concentrations tested. The
HCC1569 cell-line demonstrated the greatest sensitivity to the majority
of the tested compounds while podophyllotoxin proved to be especially
potent with a relative cell-count below 50% at the lowest tested con-
centration of 0.3 nM in 5 of the cell-lines. Interestingly, the cell pro-
liferation assay did not readily discern differences between protripty-
line and triflupromazine which induced a distinct phenotypic response
between cell lines as determined by the cell painting assay with com-
pound concentrations up to 1 μM (Fig. 3 and Table 2). These results
suggest that the Cell Painting assay provides a more sensitive and rapid
readout for detection of cell growth and viability phenotypes at sub-
lethal concentrations of drug and/or prior to overt growth inhibition or
cytotoxicity effects. Furthermore, the added phenotypic information
pertaining to drug MOA including effects on cell cycle, cytokinesis and
cytoskeletal morphology elucidated by the high content Cell Painting
assay provides added value relative to univariate cell growth and cy-
totoxicity analysis. Other advantages of high content Cell Painting and
TCCS analysis for in vitro pharmacogenomic studies over traditional cell
proliferation and viability assays include: Speed (48 h phenotypic assay
relative to long-term 3-, 5- or 7-day viability or growth assays); Single-
point concentration testing relative to dose-response testing sub-
stantially influencing throughput; Suitability for discriminating phe-
notypic response in heterogeneous cell subpopulations or co-culture
assays. Applicable to any assay or endpoint that can be discerned by
image-based phenotypic analysis including disease models and ther-
apeutic classes not defined by cell growth or viability.
Of the top 15 compound induced-phenotypic differences between
cell lines determined by Cell Painting and TCCS analysis, half involved
HCC1954 cells. Among the top 12 FDA-approved drugs which promote
distinct phenotypic response between cell lines are 4 structurally dis-
tinct small molecule drugs with previously reported serotonin mod-
ulator activity; fluvoxamine, cisapride, protriptyline and tri-
flupromazine. Fluvoxamine (DrugBank #DB00176) is an approved
antidepressant which functions pharmacologically as a selective ser-
otonin reuptake inhibitor. Fluvoxamine blocks the reuptake of ser-
otonin at the serotonin reuptake pump of the neuronal membrane,
enhancing the actions of serotonin on 5HT1A autoreceptors. Studies
have also demonstrated that fluvoxamine has virtually no affinity for
α1- or α2-adrenergic, β-adrenergic, muscarinic, dopamine D2, hista-
mine H1, GABA-benzodiazepine, opiate, 5-HT1, or 5-HT2 receptors.
Cisapride (DrugBank #DB00604) was approved as a treatment for
heartburn due to gastroesophageal reflux disease. Cisapride acts
through the stimulation of the serotonin 5-hydroxytryptamine (5-HT4,
5-HT3A, 5-HT2A) receptors which increases acetylcholine release in the
enteric nervous system. Cisapride does not induce muscarinic or nico-
tinic receptor stimulation, nor does it inhibit acetylcholinesterase ac-
tivity. Triflupromazine (DrugBank #DB00508) is a member of a class of
drugs called phenothiazine’s and is used to treat schizophrenia and
other psychotic disorders. Triflupromazine binds to the dopamine D1
and dopamine D2 receptors and inhibits their activity. Triflupromazine
also binds the muscarinic acetylcholine receptors (M1 and M2) and the
serotonin receptor 5-HT2. Protriptyline (DrugBank #DB00344) is a
dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs
are structurally similar to phenothiazines and are potent inhibitors of
serotonin and norepinephrine reuptake and also block histamine H1
receptors, α1-adrenergic receptors and muscarinic receptors.
Serotonin has recently emerged as a growth factor for several
human tumor cell types and the pattern of serotonin receptor subtype
expression becomes dysregulated in several human tumors when
compared with normal cells.31 The serotonin-induced signaling
Table 1
Number of active compounds in the Prestwick library per
cell-line.
Cell line # active compounds
HCC1569 283
HCC1954 182
KPL4 236
MCF7 287
MDA-MB-157 96
MDA-MB-231 352
SKBR3 218
T47D 327
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pathways that promote tumor progression are however complex and
only partly understood, however serotonin receptors are expressed in
breast cancer cells and tissue32–34 and serotonin receptor expression
correlates with estrogen and HER2 receptor expression.34 Further,
analysis of the target genes for protriptyline (SLC6A2 and SLC6A4) and
triflupromazine (HTR2B, CHRM1, CHRM2, DRD1, and DRD2) as well as
their wider family members using RNAseq data from the Cancer Cell
Line Encyclopedia (Supplementary Fig. S2) demonstrated expression of
CHRM1, DRD2, HTR2B, SLC6A2 and SLC6A4 in 54 breast cancer cells,
including the cancer cell lines we have used in our study. Therefore, we
selected two serotonin targeting hit compounds, protriptyline and tri-
flupromazine to study in more detail in the HCC1954 cells and T47D
cells. Protryptyline and triflupromazine both induced a similar pheno-
typic difference between HCC1954 and T47D cells in the Cell Painting
assay at 1 μM, a concentration that did not reduce cell number. Changes
in cell morphology became more pronounced when the concentration
range was expanded up to 10 μM (Fig. 4A), with the T47D cells dis-
playing a reduced number of cells and morphological changes in re-
sponse to compound treatment which was not observed in HCC1954
cells. Furthermore, T47D cells were more sensitive to growth inhibition
following protriptyline or triflupromazine treatment than the HCC1954
cells, as assessed by quantifying nuclei counts and cell viability after
48 h treatment (Fig. 4B and C). Taken together, this data demonstrates
that cellular phenotypic profiling using the Cell Painting assay, at sub-
toxic/cytostatic compound concentrations, can be used to predict toxic/
cytostatic compound effects observed using a broader range of con-
centrations in a cell viability/cell count assay.
Fig. 2. Chemical structures of hit compounds that are phenotypically different between cell line pairs.
Table 2
Hits selected from the Prestwick library which produced distinct phenotypic
responses between cell-lines. SERT: serotonin reuptake transporter, SSRI: se-
lective serotonin reuptake inhibitor, 5-HT: 5-hydroxytryptamine, D1/2 dopa-
mine receptor.
Compound Usage/MoA
Amodiaquine Anti-malarial
Cisapride 5-HT4 agonist
Dilazep Vasodilator. Adenosine reuptake inhibitor
Fluvoxamine Anti-depressant. SSRI
Ivermectin Anti-helmintic. GluCl agonist
Niclosamide Anti-helmintic
Paroxetine Anti-depressant. SSRI
Pirenperone 5-HT2A antagonist
Podophyllotoxin Microtubule destabiliser
Protriptyline Tricyclic anti-depressant. NA, SERT
Triflupromazine Antipsychotic. D1, D2 antagonist
Zalcitabine Nucleoside reverse transcriptase inhibitor
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To elucidate the molecular changes in HCC1954 and T47D cells
following treatment with protriptyline and triflupromazine, we isolated
RNA after 24 h of compound treatment and profiled the changes in gene
expression using the Pan-Cancer panel from NanoString consisting of
770 cancer related genes. Gene expression analysis revealed a large
number of significantly changed genes following triflupromazine
treatment in T47D cells but not HCC1954 cells (Fig. 5A). Differential
analysis of drug-induced gene expression changes relative to DMSO in
T47D cells revealed a number of significantly up and down regulated
genes following treatment with triflupromazine (Fig. 5B and C). Net-
work analysis of significantly (p < 0.05) up- and down-regulated
genes following triflupromazine revealed two large connected networks
of genes (Fig. 6). A large network of down regulated cell cycle asso-
ciated genes including core regulators of the cell cycle (Fig. 6A) such as
Fig. 3. Concentration-response curves for 12 hits from the Prestwick Chemical Library. Compounds were used in a 2D cell proliferation assay measuring cell count
expressed as the percentage of the DMSO control after 72 h. Note: compounds were originally screened at a concentration of 1 μM using the Cell Painting assay.
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CCND1 (cyclin D1), CCNE2 (cyclin E2) and CCNA2 (cyclin A2). En-
richment analysis of the upregulated gene set revealed activation of the
TNFR1 signaling pathway suggesting induction of apoptosis via TNF
signaling (Fig. 6B). Interestingly, HCC1954 have a missense point
mutation in TRAF2 (Q457L)18 located in the receptor binding TRAF-C
domain. TRAF2 is a key mediator of TNF receptor signaling. The
functional significance of TRAF2 (Q457L) mutation is unclear, however
such a missense mutation may impact upon TNF signaling and cell
Fig. 4. Effects of protriptyline and triflupromazine using nuclei/cell counting and viability assays in T47D and HCC1954 cells. (A) Cell lines treated with protriptyline
or triflupromazine for 48 h. Scale bar is 100 μm. (B) Quantification of nuclear counts (top) after 48 h and cell viability (bottom) after 72 h of compound treatment.
n= 3, mean± SEM is shown. STS, staurosporine (300 nM). (C) Table of EC50 values for growth inhibition.
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survival signaling during tumor development and response to
therapy.35 Serotonin is important in mammary gland development, in
part produced by the enzyme tryptophan hydroxylase (TPH) expressed
by mammary epithelial cells36 and TPH1 expression is elevated in
tumor cells34 (Supplementary Fig. S2).
Up to one-quarter of breast cancer patients suffer clinically sig-
nificant depression in the year after diagnosis and about half may be
prescribed a psychotropic medication, such as a selective serotonin
reuptake inhibitor (SSRI), while completing breast cancer therapy.
Epidemiology studies on breast cancer recurrence risk related to con-
current use of SSRI antidepressants and tamoxifen indicated breast
cancer patients taking SSRIs were at no increased risk of developing
breast cancer37 or breast cancer recurrence.38 Another study highlights
SSRIs which inhibit P450 2D6 (CYP2D6), necessary for the bioactiva-
tion of tamoxifen, reduce tamoxifen’s effectiveness and contributed to
increase mortality when the SSRI paroxetine is used concurrently with
tamoxifen.39 Our results call for further retrospective epidemiology
studies on the use of serotonin receptor modulators which do not inhibit
P450 or are administered independent of tamoxifen, however, con-
siderable variation in the prescribing patterns of SSRI antidepressants
across the world, with few studies reporting robust data on exact dose
or follow‐up regimens may confound this analysis.40 In addition,
Fig. 5. Gene expression analysis of compound treatments in T47D and HCC1954 cell lines. (A) Heatmap of gene expression following 24 h treatment with compound.
(B) Differential gene expression analysis of gene changes following triflupromazine treatment for 24 h in the T47D cell line. (C) Differential gene expression analysis
of gene changes following protriptyline treatment for 24 h in the T47D cell line. For (B) and (C), genes significantly altered (p < 0.05, Benjamini–Yekutieli-corrected
test) are highlighted; up-regulated (red circles) or down-regulated (blue circles). Gene names are displayed for genes with log2(fold change) greater than 3 or less
than -3.
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further investigation of serotonin signaling modulation across a broader
panel of genetically distinct breast cancers and the interplay with ac-
tivation of the TNF pathway is needed.
3. Conclusions
We have applied a high content Cell Painting assay and the Theta
Comparative Cell Scoring (TCCS) method to quantify a similarity score
of phenotypic response between genetically distinct breast cancer cell
types. TCCS was used to identify four serotonin modulator small mo-
lecules (fluvoxamine, cisapride, protriptyline and triflupromazine)
which rank among the top 12 FDA approved compounds promoting the
most distinct phenotypic response between breast cancer cell lines.
NanoString transcriptomic profiling and pathway network analysis was
applied to demonstrate that triflupromazine exerts selective activity
upon the inhibition of multiple cell cycle pathways and upregulation of
TNF receptor signaling in sensitive relative to non-sensitive breast
cancer lines. While the current study has made use of a diverse panel of
established breast cancer cell lines which may have limited utility in
guiding personalized medicine strategies, the methods and results
presented in this article demonstrate the value of multiparametric high
content phenotypic profiling and pathway network analysis. These
methods can also be applied to isogenic and primary patient-derived
cell assays composed of genetically distinct cell types to advance
Fig. 6. Interaction network analysis of differentially expressed genes in triflupromazine treated T47D cells. (A) Network of cell cycle related genes. (B) Network of
TNFR1 signalling genes.
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phenotypic screening, drug repurposing and future pharmacogenomic
analysis across diverse phenotypes.
4. Experimental
4.1. Cell culture
Cell-lines were all grown in DMEM (#21969-035 Gibco) and sup-
plemented with 10% fetal bovine serum and 2mM L-glutamine, in-
cubated at 37 °C, humidified and 5% CO2. Optimized cell number per
384 well plate: HCC1569 (1500 cells/well); HCC1954 (1500 cells/
well); KPL4 (750 cells/well); MCF7 (1500 cell/well); MDA-MB-231
(750 cell/well); MDA-MB-157 (2000 cells/well); SKBR3 (2000 cells/
well); T47D (1500 cell/well). Optimized cell number per 96 well plate:
HCC1569 (3000 cells/well); HCC1954 (3000 cells/well); KPL4 (2000
cells/well); MCF7 (3000 cell/well); MDA-MB-231 (2000 cell/well);
MDA-MB-157 (3500 cells/well); SKBR3 (3500 cells/well); T47D (3000
cell/well). Cells were seeded in 96- or 384-well optical bottomed
imaging plates (#655090 and #781091 Greiner) for image based as-
says, respectively or standard 96 well plates for all other assays
(#655180 Greiner). Plates were incubated for 24 h in a tissue culture
incubator before the addition of compounds.
4.2. IncuCyte proliferation assay
The lentiviral based IncuCyte® NucLight Reagent (Sartorius) was
used to label all breast cancer cell lines with a nuclear-restricted green
fluorescent protein (GFP) to enable accurate quantification of cell
growth over time. The IncuCyte® platform acquired images and calcu-
lated the number of cell nuclei to provide a cell count assay endpoint at
sequential time points following cell plating and compound treatment.
All analyses presented was performed at 72 h following compound
treatment. Note: the morphology and growth rate of the GFP-NucLight
labelled cells were confirmed to behave similarly to parental cell lines.
NucLight cells were used for the IncuCyte® cell proliferation experiment
only, parental cell lines were used for Cell Painting, cell viability and
NanoString experiments.
4.3. Cell viability assay
For cell viability assays, seeding density for 96-well plate assay
format was optimized for each individual cell line to ensure a linear
assay range. Cells were seeded in 96 well plates and cultured for 24 h
before treatment. Cells were incubated with compounds for 72 h, un-
treated cells were incubated with 0.1% DMSO (v/v). Alamar Blue
(Invitrogen, Paisley, UK) was added (10% v/v) to each well and plates
incubated for 3 h. Fluorescence emission was read on an EnVision 2101
multilabel plate reader (PerkinElmer; excitation=540 nm, emis-
sion=590 nm). All conditions were normalized to plate DMSO control
wells.
4.4. Prestwick compound library handling
Handling of the Prestwick FDA-approved compound library was
performed using a Biomek FX. 1.5 μL from master plates containing
1mM compound in DMSO was transferred to an intermediate plate
containing 74.5 μL of cell culture media for a 1:50 dilution. From the
intermediate plate 2.5 μL was transferred to the cell assay plate con-
taining 50 μL volume for a second dilution of 1:20 resulting in a final
1;1000 dilution of compound stock at 0.1%DMSO (v/v) in each assay
well. Assay plates were barcoded with cell-line and a sequential number
corresponding to the compound source plate.
4.5. Cell Painting staining protocol
Cell Painting21 and our modified protocol for our panel of breast
cancer cell lines is described in.25,26 Briefly, cells are fixed by adding an
equal volume of 8% paraformaldehyde (#28908 Thermo Scientific) to
the existing media resulting in a final paraformaldehyde concentration
of 4%, and left to incubate for 30min at room temperature. The plates
are then washed with PBS and permeabilized with 0.1% Triton-X100
solution for 20min at room temperature. A solution of Cell Painting
reagents (Hoeschst 33342; SYTO14; Phalloidin-594: Wheat germ ag-
glutinin-594; Concavalin-488; MitoTracker DeepRed) was made up in
1% bovine serum albumin (BSA) solution. Cell Painting solution was
added to plates and incubated for 30min at room temperature in a dark
place. Plates were then washed with PBS three times, and plates were
sealed with a plate seal. In a modification to the original Cell Painting
assay we add the MitoTracker dye following cell fixation as we found
that application of MitoTracker to MDA-MB-231 cells in culture in-
duced morphological changes. We still observe significant signal above
noise in a staining pattern resembling mitochondria and we therefore
anticipate that post-fixation staining with MitoTracker still provides
mechanistic information on mitochondrial number and structure but
without any risk of artefactual modulation of cell morphology following
live cell exposure.
We selected staurosporine as our phenotypic positive control as it
induces a distinctive change in cell morphology across all the breast
cancer cell lines at the same concentration (0.3 μM), most likely as a
consequence of its broad substrate specificity. This makes staurosporine
a very useful control compound for Cell Painting-like morphology
analysis across cell line panels, even though there is no clinical appli-
cation for this compound. Negative (0.1% DMSO) and positive (0.3 μM
staurosporine) controls were used for normalization of plate effects and
evaluation of the performance of basal cell line normalization of dis-
tinct cell morphologies (Supplementary Fig. S1).
4.6. Imaging
Imaging was carried out on an ImageXpress micro XL (Molecular
Devices, USA) a multi-wavelength wide-field fluorescent microscope
equipped with a robotic plate loader (Scara4, PAA, UK). Images were
captured in 5 fluorescent channels at 20× magnification, exposure
times were kept constant between plates and batches as to not influence
intensity values.
4.7. Image analysis
Images were analyzed using CellProfiler v2.1.1 to extract morpho-
logical features, quantifying 340 morphological features per cell.
Briefly, cell nuclei were segmented in the Hoechst stained image based
on intensity, clumped nuclei were separated based on shape. Nuclei
objects were used as seeds to detect and segment cell-bodies in the
cytoplasmic stains of the additional channels. Subcellular structures
such as nucleoli and Golgi apparatus were segmented and assigned to
parent objects (cells). Using these masks marking the boundary of cel-
lular objects, morphological features are measured for multiple image
channels returning per object measurements.
4.8. Data analysis
Pre-processing: Out of focus and low-quality images were detected
through saturation and focus measurements and removed from the
dataset. Image averages of single object (cell) measurements were ag-
gregated by taking the median of each measured feature per image.
Feature selection was performed by calculating pair-wise correlations of
features and removing one of a pair of features that have correlation
greater than 0.9, and removing features with very low (<1e−5) or zero
variance. To normalize the inherent morphological variation between
cell lines, features were standardized on a plate-by-plate basis by di-
viding each feature by the median DMSO response for that feature and
scaled by a z-score (z) to a zero mean and unit variance. Tabular data
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from CellProfiler measuring morphological features for each cell was
aggregated to an image median. Principal components were calculated
using the prcomp function in R v3.2, with no centering or scaling as this
was performed manually beforehand. The number of principal com-
ponents to use in the analysis can be determined by specifying be-
forehand the proportion of variance in the data that should be kept, and
then finding the minimum number of principal components that ac-
count for that proportion of variance in the dataset.
In order to center the principal component data so that the medoid
of the negative control was positioned on the origin, the median value
for each feature column for the negative control data was calculated.
Then by calculating how much this differs from the origin for each
feature, all principal component values were adjusted by this differ-
ence. Inactive compounds were identified by determining a minimum
cut-off distance to the negative control centroid in principal component
space. This was calculated by first finding the l1 norm from each
compound to the negative control centroid. The standard deviation of
all these distances was calculated and any compound which was within
2 standard deviations of the negative control centroid was deemed in-
active, if a compound was found to be inactive in any one of the eight
cell lines it was removed from the analysis.
Phenotypic characterization: Following data pre-processing, distinct
phenotypic responses between active compounds were calculated using
the TCCS method.25,26 An initial hit list was created by ranking com-
pounds and cell-line pairs by decreasing Δθ. Compounds were triaged
by removing those with less interesting mechanistic properties such as
microtubule disruptors leaving 14 hits. From these 14 hits, 2 were not
easily available due to lack of a commercial supplier (pinaverium
bromide) or being a controlled substance (3,4-dimethox-
yphenethylamine). For each hit compound Δθ values were calculated
between all pairs of cell-lines for each, and ranked by order of de-
creasing Δθ, so that compound-cell-line-pairs with a more distinct
phenotypic response received a lower rank. A rank product41 was cal-
culated from the replicates and compound-cell-line-pairs were sorted by
increasing rank product.
4.9. RNA isolation and NanoString analysis
T47D and HCC1954 cells were seeded in 6 well plates for 24 h be-
fore drug treatment for a further 24 h. Media was removed and RNA
was extracted using an RNeasy Mini Kit with on column DNAse di-
gestion (#74104 and #79254 Qiagen) following the manufacturer’s
protocol. RNA quality was assessed using A260/A280 ratio and con-
centrations normalized. 100 ng of RNA was analyzed by the using an
nCounter® PanCancer Pathways Panel (XT-CSO-PATH1-12,
NanoString). Gene expression data was analyzed using nSolver software
(NanoString) and data was normalized following the NanoString pro-
tocol and analyzed using the advanced analysis module to calculate
differential ratios between different drug treatments. Data was exported
into Cytoscape42 and gene networks constructed using the GeneMania
app43 and functional enrichment was performed using Gene On-
tology.44
4.10. Cancer cell line expression RNAseq analysis
RNAseq datasets (19Q3 release) from 54 breast cancer cell lines
from the Cancer Cell Line Expression (broadinstitute.org/ccle) was
analyzed for genes of interest. Data is RNAseq TPM (transcripts per
million) gene expression data for protein coding genes using RSEM.
Data is Log2 transformed, using a pseudo-count of 1. Database was
subset for cell lines and genes of interest and overlaid on a boxplot of
the expression data for all breast cancer cell lines in the database. Upper
and lower “hinges” correspond to the first and third quartiles. Whiskers
extend 1.5 × (interquartile range) of the hinge. Data points beyond the
end of the whiskers are outliers.
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